contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


sanionas-ceo-thomas-feldthus-participates-in-life-science-dagen-on-march-5-and-in-redeyes-investor-forum-online-on-march-6-2025

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Saniona er en svensk virksomhed, der udvikler og forsker i farmaceutiske produkter imod nervesygdomme og autoimmune sygdomme. Virksomheden har en omfattende portefølje af lægemidler under udvikling i klinisk og pre-kliniske stadier. Derudover samarbejder de også med andre forskningsbaserede virksomheder om udvikling af nye produkter. Saniona har hovedkontor i Glostrup.

Saniona

Saniona, a clinical-stage biopharmaceutical company, announces that the company’s CEO, Thomas Feldthus, will participate at Life Science-dagen 2025 at Wallenberg’s conference center, Gothenburg...

<div class="mfn-preamble"><p><strong>Saniona, a clinical-stage biopharmaceutical company, announces that the company’s CEO, Thomas Feldthus, will participate at Life Science-dagen 2025 at Wallenberg’s conference center, Gothenburg, on March 5 at 2:15 pm CET and at Redeye’s Investor Forum Online on March 6 at 2 - 4 pm CET.</strong></p></div><div class="mfn-body"><p>Both events will be live broadcasted at <a rel="noopener" href="http://www.lifesciencedagen.se/">www.lifesciencedagen.se</a> and at <a rel="noopener" href="https://www.redeye.se/events?tab=upcomingevents">Events - Redeye</a> respectively.</p></div><div class="mfn-footer mfn-contacts mfn-aa1485cfdb51"><p><strong class="mfn-heading-1">For more information, please contact</strong><br>Thomas Feldthus, CEO, +45 22109957; <a rel="noopener" href="mailto:thomas.feldthus@saniona.com">thomas.feldthus@saniona.com</a></p></div><div class="mfn-footer mfn-about mfn-0d44ab45ae41"><p><strong class="mfn-heading-1">About Saniona</strong><br>Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of neurological disorders. Saniona’s internal pipeline includes SAN2219, targeting acute repetitive seizures; SAN2355, addressing refractory focal onset seizures; and SAN2465, positioned for major depressive disorders. Saniona has two strategic development collaborations. SAN711 is being prepared for Phase 2 for essential tremor in collaboration with Acadia Pharmaceuticals and tesofensine is out licensed for obesity to Medix, which has submitted a market authorization application (MAA) in Mexico. In addition, Saniona oversees two clinical programs poised for collaboration. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.<br>For more information, visit <a rel="noopener" href="http://www.saniona.com">www.saniona.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/67323562-ba89-4b88-99fd-411f2de67148/sanionas-ceo-thomas-feldthus-participates-in-life-science-dagen-on-march-5-and-in-redeyes-investor-forum-online-on-march-6-2025.pdf" class="mfn-generated mfn-primary">Saniona's CEO, Thomas Feldthus, participates in Life Science-dagen on March 5 and in Redeye’s Investor Forum Online on March 6, 2025</a></p></div>

Saniona's CEO, Thomas Feldthus, participates in Life Science-dagen on March 5 and in Redeye’s Investor Forum Online on March 6, 2025